ClinicalTrials.gg
RecruitingNCT04806464Updated Sep 19, 2024

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

A Phase 1 interventional study of Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in Primary Liver Cancer, sponsored by CNBG-Virogin Biotech (Shanghai) Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by CNBG-Virogin Biotech (Shanghai) Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
666th of 1,038
44 · median 77
Started
2021
with 116 others
Phase 1
139 of 1,314
61 open now
Primary completion
2022-03
later than 5 of 560 live
Registered
581st of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 666th largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 117 that started in 2021, is one of 139 in phase 1, reaches primary completion later than 5 of the 560 other live ones, and was the 581st registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies. This is an open label study and it's divided into two parts.

Part 1: This part is ascending dose design to determine the safety and tolerability of VG161 and find recommended dose of VG161.

Part 2: This part is extended dose design to determine the effectiveness of VG161.

Read the detailed description

Part 1: This part will be conducted in 5 dose ascending cohorts, including 2 accelerated titration design dose group and 3 dose escalation groups. Descriptive statistics will be used to summarize data.

Part 2: This part will only include the part 1 recommended dose. Hypothesis test and descriptive statistics will be used to summarize data.

03

Conditions studied

  • Primary Liver Cancer

Keywords

  • Liver Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. According to 'The Diagnostic and Therapeutic Criteria for Primary Liver Cancer' (NMPA, 2019 Edition), subject with advanced primary hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular which is /relapsed after and/or intolerant of standard therapies or for which no standard therapy exists. For the second stage of Simon\'s two-stage in part 2, only patients with advanced primary hepatocellular carcinoma will be enrolled.
  2. There are tumor lesions intrahepatic and / or extrahepatic that can be injected under B ultrasound and meet the volume requirements of the current dose group, and the longest diameter of injectable tumor lesion >1.5cm(or the shortest diameter of lymph node lesions)
  3. (ECOG) scores 0 or 1.
  4. is at least 3 months.
  5. Required organ function:
  1. Hematology blood (no blood transfusion or colony stimulating factor treatment within 14 days): (ANC)≥1.5×10\^9L, (PLT)≥75×10\^9L, (Hb)≥85g/L; 2) Liver function: Total Serum (TBIL)≤1.5× (the upper limit of the reference range), (ALT)≤5×ULN, aspartate aminotransferase (AST)≤5×ULN; 3) A-B level; 4) Renal function: Serum creatinine≤1.5×ULN, and ≥45 ml/min (calculated per Cockcroft-Gault formula); 5) Coagulation function: (APTT)≤1.5×ULN, prothrombin time(PT) ≤1.5×ULN, international standardized ratio (INR)≤1.5×ULN.
  1. Subjects who are negative; or HBV-DNA positive are required to receive treatment in accordance with the 'Guidelines for the prevention and treatment of chronic hepatitis B' (2019 Edition) or clinical practice.

7.Subjects of (male and female) must agree to use a reliable method (hormone or barrier method or abstinence) during the study and for at least 90 days following the last dose; females of childbearing potential must have a negative blood pregnancy test within 7 days of study enrollment.

8.Signed written .

Exclusion Criteria:

  1. Subject in prior anti-tumor therapies such as chemotherapy, radiotherapy, biotherapy, endocrinotherapy, targeted therapy, immunotherapy within 4 weeks of study treatment initiation. Oral fluorouracil analogues and small molecule targeted drugs were 2 weeks prior to the first dose of study drug or within 5 half-lives of the drug (whichever was longer).
  2. Transcatheter arterial chemoembolization(TACE) within 4 weeks of study treatment initiation
  3. Participation in clinical trials of any other agents within 4 weeks of study treatment initiation.
  4. Major organ surgery (excluding puncture ) or significant trauma within 4 weeks of study treatment initiation.
  5. Patients who received systemic treatment with either ( >10 mg/ daily prednisone or equivalent) or other medications within 14 days of study treatment initiation.
  6. Subjects with any ≥Grade 1 toxicity (as per NCI CTC AE Version 5.0) related to prior anti-cancer therapy (except for toxicity that the investigator assessed to be no safety risk, such as alopecia.).
  7. Subjects with Central Nervous System (CNS) metastasis or meningeal metastasis .
  8. Seronegative for Herpes Simplex Virus (HSV) (HSV-1IgG and HSV-1IgM).
  9. Subjects with the relapse of HSV infection and relevant clinical manifestations, such as lip herpes, herpes keratitis, herpes dermatitis, and genital herpes.
  10. Subjects with other uncontrolled active infections.
  11. Known history of immunodeficiency and test positive of (HIV).
  12. History of severe cardiovascular disease:

1)Ventricular arrhythmias requiring clinical intervention; 2) >480 ms; 3)Acute coronary syndrome, congestive heart failure, stroke or other cardiovascular events of III grade or above within 6 months; 4)The cardiac function grade≥II or (LVEF) \<50% per the (NYA); 5)Uncontrolled hypertension.

  1. Subjects with active or past diseases that are likely to recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.); acceptable for patients with clinically stable autoimmune thyroiditis.
  1. Previous immunotherapy with an immune-related adverse event (irAE) such as immune-related pneumonia, myocarditis, etc., which, in the judgement of the investigator, may affect the safety of the investigational drug. 15. known to have alcohol or drug dependence. 16. Persons with mental disorders or poor compliance. 17. Pregnant or lactating women. 18. Subjects with any significant unrelated systemic illness that to the investigator's opinion would compromise the subject's eligibility to participate the study.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    VG161

    Part1: 1. 1.0\*10\^8 PFU on Day 1(1.0×10\^8PFU) 2. 1.0\*10\^8 PFU on Days 1 to 2(2.0×10\^8PFU) 3. 1.0\*10\^8 PFU on Days 1 to 3(3.0×10\^8PFU) 4. 1.3\*10\^8 PFU on Days 1 to 3(4.0×10\^8PFU) 5. 1.7\*10\^8 PFU on Days 1 to 3(5.0×10\^8PFU) Part2: Depends on the recommended dose in Part1

    Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

Interventions

06

What researchers measure

Primary outcomes

  1. Part1: MTD/Recommended dose

    MTD (Maximum tolerable dose) /Recommended dose

    Time frame: 7 month

  2. Part1: Occurence of DLT

    Occurence of DLT (Dose Limiting Toxicity)

    Time frame: 1month

  3. Part1: Numbers of DLT

    Numbers of DLT (Dose Limiting Toxicity)

    Time frame: 1 month

  4. Part1: Occurence of AE and SAE(NCI CTCAE 5.0)

    Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0)

    Time frame: 7 months

  5. Part1: Frequency of AE and SAE(NCI CTCAE 5.0)

    Frequency of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0)

    Time frame: 7 months

  6. Part2:ORR

    Evaluate Objective Response Rate by RECIST 1.1

    Time frame: 7 months

Secondary outcomes

  1. Part1:Tmax(h)

    Time to peak

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Part1:Cmax(copies/ugDNA)

    Maximum concentration

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Part1:ORR

    Evaluate Objective Response Rate by iRECIST

    Time frame: 7 months

  4. Part1:DOR

    Evaluate Disease Control Rate by iRECIST

    Time frame: 7 months

  5. Part1:PFS

    Evaluate medium Progression Free Survival by iRECIST

    Time frame: 7 months

  6. Part1:OS rate

    Evaluate Overall Survival rate

    Time frame: 17 months

  7. Part 1:CD3+, CD4+, CD8+

    Concentration of CD3+, CD4+, CD8+

    Time frame: 7 months

  8. Part 1:IL15

    Concentration of IL15

    Time frame: 7 months

  9. Part 1:PD-L1, PD-1

    Concentration of PD-L1, PD-1

    Time frame: 7 months

  10. Part 2:PFS

    Evaluate medium Progression Free Survival by iRECIST

    Time frame: 7 months

  11. Part 2:OS rate

    Evaluate Overall Survival rate

    Time frame: 17 months

  12. Part 2: OS

    Overall Survival

    Time frame: 17 months

  13. Part 2:DOR

    Evaluate Disease Control Rate by iRECIST

    Time frame: 7 months

  14. Part 2:Safety indicators:AEs

    Incidence of adverse events (NCI CTCAE 5.0)

    Time frame: 7 months

  15. Part 2:Safety indicators:ECOG

    Incidence of abnormal ECOG scores

    Time frame: 7 months

  16. Part 2:Safety indicators:12-lead electrocardiograms

    Incidence of abnormal 12-lead electrocardiograms

    Time frame: 7 months

  17. Part 2:Safety indicators:laboratory tests results

    Incidence of abnormal laboratory tests results

    Time frame: 7 months

  18. Part 2:CD3+, CD4+, CD8+

    Concentration of CD3+, CD4+, CD8+

    Time frame: 7 months

  19. Part 2:IL15

    Concentration of IL15

    Time frame: 7 months

  20. Part 2:PD-L1, PD-1

    Concentration of PD-L1, PD-1

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2022, 12 months.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 12 months is below that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2021
First posted
Mar 19, 2021
StartActual
Mar 16, 2021
Primary completionActual
Mar 21, 2022
CompletionEst.
Dec 31, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04806464
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Mar 16, 2021
Primary completion
Mar 21, 2022
Completion
Dec 31, 2024 (estimated)
Last update
Sep 19, 2024

Study contacts

Tingbo Liang, MD.PhD.
Contact
liangtingbo@zju.edu.cn
0571-87236666
Tingbo Liang
principal investigator · Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oncolytic HSV-1 Expressing IL-12, IL-15/IL-15-receptor Alpha and PD-L1 Blocking Peptide VG161

Start the discussion